Dr. Ramchandren on the North American Results of the ECHELON-1 Study in Hodgkin Lymphoma

Radhakrishnan Ramchandren MD

Radhakrishnan Ramchandren MD, associate professor, Wayne State University School of Medicine, Barbara Ann Karmanos Cancer Institute, discusses the North American results of the ECHELON-1 study in Hodgkin lymphoma.

The phase III ECHELON-1 trial compared brentuximab vedotin (Adcetris) plus doxorubicin, vinblastine, and dacarbazine (A+AVD) with doxorubicin (Adriamycin), bleomycin, vinblastine, and dacarbazine (ABVD) in patients with newly diagnosed Hodgkin lymphoma. The North American subgroup analysis of the ECHELON-1 trial was evaluated due to potential regional differences in outcomes that were presented in the primary study at the 2017 ASH Annual Meeting.

The global study indicated a 5% benefit with A+AVD in modified progression-free survival (PFS). That benefit was not distributed globally, notes Ramchandren. In the North American subgroup analysis, modified PFS per independent review facility at 2 years was 84.3% and 73.7% with A+AVD versus ABVD, respectively.

Patients in North America who received A+AVD experienced an estimated 2-year PFS per investigator review and modified PFS benefits that ranged from 10.6% to 12.8% compared with ABVD. It is unclear why that benefit exists, but the number of patients on the North American subgroup analysis was substantial, accounting for approximately 40% of patients enrolled on trial.
Printer Printing...